Abstract This 2022 European Atherosclerosis Society lipoprotein (a)[Lp (a)] consensus
statement updates evidence for the role of Lp (a) in atherosclerotic cardiovascular disease …

Calcific aortic valve disease (CAVD) is a highly prevalent condition that comprises a disease
continuum, ranging from microscopic changes to profound fibro-calcific leaflet remodelling …

Rates of atherosclerotic cardiovascular diseases (CVD) in the Western world have
spectacularly decreased over the past 50 years. However, a substantial proportion of high …

Prolonged or excessive exposure to oxidized phospholipids (OxPLs) generates chronic
inflammation. OxPLs are present in atherosclerotic lesions and can be detected in plasma …

Importance There are currently no pharmacological treatments available to slow
hemodynamic progression of aortic stenosis. Plasma lipoprotein (a) concentrations predict …

Lipoprotein (a)(Lp (a)) is an established risk factor for multiple cardiovascular diseases.
Several lines of evidence including mechanistic, epidemiologic, and genetic studies support …

Despite numerous promising therapeutic targets, there are no proven medical treatments for
calcific aortic stenosis (AS). Multiple stakeholders need to come together and several …

Although evidence indicates the association of lipoprotein (a)[Lp (a)] with atherosclerosis,
the link with calcific aortic valve disease (CAVD) is unclear. This systematic review and meta …

Calcific aortic valve stenosis (CAVS), the most common heart valve disease, is characterized
by the slow progressive fibro-calcific remodeling of the valve leaflets, leading to progressive …

Abstract Purpose of Review This review summarizes the pathophysiology of calcific aortic
valve stenosis (CAVS) and surveys relevant clinical data and basic research that explain …